Charles Drescher, MD
Gynecological Oncology · Seattle, WANPI 1710939855
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,250 of the $7,216 with a category attached, or 72.8%. Boston Scientific accounts for 79.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $5,929 and has fallen 97.9% since, to $125 in 2024.
Across 12 payments — averaging $601.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$6K
- Intuitive Surgical$1K
- AstraZeneca$217
- Clovis Oncology, Inc.$83
- Sanofi-aventis U.S. LLC$20
- Puma Biotechnology, Inc.$17
Across 70 payments — averaging $18,315 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$735K
- Novartis$297K
- E.r. Squibb & Sons, L.L.C.$187K
- AstraZeneca$40K
- Merck$17K
- Boston Scientific$6K
What the payments were for
- Consulting fees$5,25073%
- Travel & lodging$4917%
- Food & beverage$4506%
- Education$1,02614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $5,755 |
| Intuitive Surgical | 3 | $1,125 |
| AstraZeneca | 2 | $217 |
| Clovis Oncology, Inc. | 1 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL UTERINE TISSUE REMOVAL$5,250
- DAVINCI XI$1,000
- GENERAL - THERAPIES$431
- LYNPARZA$125
How this compares
Too few gynecological oncology providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 19 | $386,427 |
| Everolimus | 13 | $25,000 |
| EliquisApixaban | 15 | $10,891 |
| Megestrol Acetate | 19 | $522 |
| Gabapentin | 18 | $224 |
| Prochlorperazine Maleate | 31 | $222 |
| Dexamethasone | 20 | $214 |
| Letrozole | 13 | $147 |
| Oxycodone Hcl | 19 | $127 |
| Ondansetron Hcl | 23 | $122 |
| Lorazepam | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other gynecological oncology in Seattle
- Dan VeljovichSeattle$780K
- Pamela PaleySeattle$2K
- Isabel RodriguezSeattle$0
- Barbara GoffSeattle$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.